Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review

References

• Papini M, Natalini Y. Candida infections in psoriatic patients on anti-IL17 therapy: a case series. J Dermatolog Treat. 2018;29(sup2):3–4.
   PubMed Web of Science ®Google Scholar
• Tschudy J, Michail S. Disseminated histoplasmosis and pneumocystis pneumonia in a child with Crohn disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2010;51(2):221–222.
   PubMed Web of Science ®Google Scholar
• Marchand T, Revest M, Tattevin P, et al. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(3):643–645.
   PubMed Web of Science ®Google Scholar
• Blinkenberg M, Soelberg Sørensen P. Monoclonal antibodies for relapsing multiple sclerosis: a review of recently marketed and late-stage agents. CNS Drugs. 2017;31(5):357–371.
   PubMed Web of Science ®Google Scholar
• Gensicke H, Leppert D, Yaldizli Ö, et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs. 2012 Jan 1;26(1):11–37.
   PubMed Web of Science ®Google Scholar
• Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709–717.
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273.
   PubMed Web of Science ®Google Scholar
• Hu Y, Nie H, Yu HH, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(5):542–548.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee H, Kim E. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-hodgkin’s lymphoma: a systematic review and meta-analysis. BioDrugs. 2019;33(5):469–483.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4): 460–471.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010;74(23):1860–1867.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–2081.
   PubMed Web of Science ®Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable Therapies. JAMA Neurol. 2019;77(2): 184–191.
   Web of Science ®Google Scholar
• Zappulo E, Buonomo AR, Saccà F, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6(11): ofz445.
   PubMed Web of Science ®Google Scholar
• Rommer PS, Dörner T, Freivogel K, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J Neuroimmune Pharmacol. 2016;11(1):1–8.
   PubMed Web of Science ®Google Scholar
• Barra ME, Soni D, Vo KH, et al. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016 Jan-Dec;2:2055217316672100.
   Google Scholar
• Naser Moghadasi A, Darki A, Masoumi P, et al. Evaluating the efficacy and safety of Zytux(TM) (rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: an observational study. Mult Scler Relat Disord. 2019;36:101419.
   PubMed Web of Science ®Google Scholar
• Scotti B, Disanto G, Sacco R, et al. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PloS One. 2018;13(5):e0197415.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835–841.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3): 221–234.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3): 209–220.
   PubMed Web of Science ®Google Scholar
• Prockl V, Nickel FT, Utz KS, et al. Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients. J Neurol Sci. 2020 Aug 15;415:116973.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839.
   PubMed Web of Science ®Google Scholar
• Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013;80(1):55–61.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med. 2008;359(17):1786–1801.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069–1078.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856): 1819–1828.
   PubMed Web of Science ®Google Scholar
• Russo CV, Saccà F, Paternoster M, et al. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler. 2020;26(1):123–126.
   PubMed Web of Science ®Google Scholar
• Chinea A, Honeycutt WD, Miller T, et al. Effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis. Int J MS Care. 2020;22(2): 53–59.
   PubMedGoogle Scholar
• Prosperini L, Annovazzi P, Boffa L, et al. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol. 2018;265(12):2851–2860.
   PubMed Web of Science ®Google Scholar
• Lau AY, Lui GCY, Chan KP, et al. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. Mult Scler Relat Disord. 2020;38:101503.
   PubMed Web of Science ®Google Scholar
• Holmøy T, Fevang B, Olsen DB, et al. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes. 2019;12(1):497.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee EJ, Kim SK, et al. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. Mult Scler Relat Disord. 2019;30:247–251.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Shin HJ, Jang H, et al. Therapeutic outcome of alemtuzumab in Korean patients with multiple sclerosis: 2-year follow-up. J Clin Neurol. 2019;15(3):328–333.
   PubMed Web of Science ®Google Scholar
• Di Ioia M, Di SV, Farina D, et al. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord. 2020;38:101504.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Michielin O, Cervera C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. The official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24 Suppl 2(Suppl2):S95–s107.
   PubMedGoogle Scholar
• Boffa G, Bruschi N, Cellerino M, et al. Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. CNS Drugs. 2020;34(4):425–432.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6): 545–556.
   PubMed Web of Science ®Google Scholar
• Achtnichts L, Obreja O, Conen A, et al. Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2015;72(10):1203–1205.
   PubMed Web of Science ®Google Scholar
• Ward MD, Jones DE, Goldman MD. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016;9:47–49.
   PubMed Web of Science ®Google Scholar
• Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature. Mult Scler Relat Disord. 2016;9:158–162.
   PubMed Web of Science ®Google Scholar
• Pham C, Bennett I, Jithoo R Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod. BMJ case reports. 2017:bcr2017220026.
   Google Scholar
• Chong I, Wang KY, Lincoln CM. Cryptococcal meningitis in a multiple sclerosis patient treated with fingolimod: a case report and review of imaging findings. Clin Imaging. 2019;54:53–56.
   PubMed Web of Science ®Google Scholar
• Ma SB, Griffin D, Boyd SC, et al. Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: case report and review of published cases. Mult Scler Relat Disord. 2020;39:101923.
   PubMed Web of Science ®Google Scholar
• Wienemann T, Müller AK, MacKenzie C, et al. Cryptococcal meningoencephalitis in an IgG(2)-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report. BMC Neurol. 2020;20(1):158.
   PubMed Web of Science ®Google Scholar
• Forrestel AK, Modi BG, Longworth S, et al. Primary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2016;73(3):355–356.
   PubMed Web of Science ®Google Scholar
• Carpenter AF, Goodwin SJ, Bornstein PF, et al. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: here come the opportunistic infections? Mult Scler. 2017;23(2):297–299.
   PubMed Web of Science ®Google Scholar
• Patil SM, Beck PP, Arora N, et al. Primary cutaneous cryptococcal infection due to fingolimod - induced lymphopenia with literature review. IDCases. 2020;21:e00810.
   PubMed Web of Science ®Google Scholar
• Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology. 2015;85(11):1001–1003.
   PubMed Web of Science ®Google Scholar
• Seto H, Nishimura M, Minamiji K, et al. Disseminated Cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod. Intern Med. 2016;55(22):3383–3386.
   PubMed Web of Science ®Google Scholar
• Samudralwar RD, Spec A, Cross AH. Case report: fingolimod and Cryptococcosis: collision of immunomodulation with infectious disease. Int J MS Care. 2019;21(6):275–280.
   PubMedGoogle Scholar
• Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197–207.
   PubMed Web of Science ®Google Scholar
• Fox E, Edwards K, Burch G, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014;3(5):607–619.
   PubMed Web of Science ®Google Scholar
• Ordoñez-Boschetti L, Rey R, Cruz A, et al. Safety and tolerability of fingolimod in Latin American patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Ther. 2015;32(7):626–635.
   PubMed Web of Science ®Google Scholar
• Laroni A, Brogi D, Brescia Morra V, et al. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurol Sci. 2017;38(1):53–59.
   PubMed Web of Science ®Google Scholar
• Chitnis T, Arnold DL, Banwell B, et al. Trial of Fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324.
   Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Chitnis T, Banwell B, Krupp L, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: results from the PARADIGMS study. Mult Scler. 2020;1352458520936934 [online ahead of print].
   Web of Science ®Google Scholar
• Kira J, Itoyama Y, Kikuchi S, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol. 2014;14(1):21.
   PubMedGoogle Scholar
• Yang CC, Ro LS, Tsai NW, et al. Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan. J Formos Med Assoc. 2021;120(1 Pt 2):542–550.
   PubMed Web of Science ®Google Scholar
• Delbue S, Comar M, Ferrante P. Natalizumab treatment of multiple sclerosis: new insights. Immunotherapy. 2017;9(2):157–171.
   PubMed Web of Science ®Google Scholar
• Clerico M, Artusi CA, Liberto AD, et al. Natalizumab in multiple sclerosis: long-term management. Int J Mol Sci. 2017;18(5):940.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806–812.
   PubMed Web of Science ®Google Scholar
• Foley J, Carrillo-Infante C, Smith J, et al. The 5-year tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord. 2019;39:101863.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660–668.
   PubMed Web of Science ®Google Scholar
• Baroncini D, Ghezzi A, Annovazzi PO, et al. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 2016;22(10):1315–1326.
   PubMed Web of Science ®Google Scholar
• Valenzuela RM, Pula JH, Garwacki D, et al. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J Neurol Sci. 2014 May 15;340(1–2):109–111.
   PubMed Web of Science ®Google Scholar
• Gundacker ND, Jordan SJ, Jones BA, et al. Acute cryptococcal immune reconstitution inflammatory syndrome in a patient on natalizumab. Open Forum Infect Dis. 2016;3(1):ofw038.
   PubMed Web of Science ®Google Scholar
• Gutwinski S, Erbe S, Münch C, et al. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010;74(6):521–523.
   PubMed Web of Science ®Google Scholar
• Blair HA. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2019;79(18):1965–1976.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, Placebo-controlled, phase III APEX study and its open-label extension. Adv Ther. 2018;35(10):1598–1611.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Workel HH, Wolfhagen M, Bouwhuis JW, et al. Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: a case report. Mult Scler Relat Disord. 2020;42:102137.
   PubMed Web of Science ®Google Scholar
• Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003.
   PubMed Web of Science ®Google Scholar
• McKeage K. Glatiramer acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs. 2015;29(5):425–432.
   PubMed Web of Science ®Google Scholar
• Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurol Sci. 2005;26(Suppl 4):S183–6.
   PubMedGoogle Scholar
• Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46.
   PubMed Web of Science ®Google Scholar
• Jacobs BM, Ammoscato F, Giovannoni G, et al. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(12):1266–1271.
   PubMed Web of Science ®Google Scholar
• Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578–593.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Teriflunomide: a review in relapsing-remitting multiple sclerosis. Drugs. 2019;79(8):875–886.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18(9):1278–1289.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546–557.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977–986.
   PubMed Web of Science ®Google Scholar
• Kallmann BA, Tiel-Wilck K, Kullmann JS, et al. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077.
   Web of Science ®Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–767.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li DK, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73(9):1089–1098.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Arnold DL, et al. Efficacy and safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study. Mult Scler. 2019;25(9):1255–1262.
   PubMed Web of Science ®Google Scholar
• Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–1020.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021–1033.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):373–381.
   PubMed Web of Science ®Google Scholar